Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 9,010,890
  • Shares Outstanding, K 143,030
  • Annual Sales, $ 418,150 K
  • Annual Income, $ -140,110 K
  • 36-Month Beta 2.39
  • Price/Sales 21.13
  • Price/Cash Flow 0.00
  • Price/Book 15.36

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.17 +22.90%
on 09/19/17
64.07 -1.84%
on 10/16/17
+9.10 (+16.92%)
since 09/15/17
3-Month
45.31 +38.80%
on 08/21/17
64.07 -1.84%
on 10/16/17
+9.16 (+17.05%)
since 07/14/17
52-Week
45.31 +38.80%
on 08/21/17
75.36 -16.55%
on 11/10/16
+12.58 (+25.00%)
since 10/14/16

Most Recent Stories

More News
Cancer Space Update: Lung & Breast Cancer Studies in Focus

While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

AZN : 34.65 (+0.12%)
MRK : 63.34 (-0.08%)
LLY : 85.95 (-0.69%)
CLVS : 84.58 (+0.37%)
ABBV : 91.04 (+0.41%)
SGEN : 62.89 (-0.17%)
Seattle Genetics Inks Clinical Collaborations for Cancer Drug

Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.

MRK : 63.34 (-0.08%)
INFI : 2.95 (+1.72%)
SGEN : 62.89 (-0.17%)
BMY : 63.65 (-2.51%)
Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics

NEW YORK, NY / ACCESSWIRE / October 12, 2017 / Both Akari Therapeutics and Seattle Genetics saw their shares climb higher on Wednesday after the companies had encouraging news about clinical trials. While...

AKTX : 6.48 (+2.21%)
SGEN : 62.89 (-0.17%)
Seattle Genetics Begins Phase II Study of Cancer Candidate

Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.

BAYRY : 35.2900 (+0.94%)
MRK : 63.34 (-0.08%)
LLY : 85.95 (-0.69%)
SGEN : 62.89 (-0.17%)
Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer

---SGN-LIV1A to be Evaluated as Part of Neoadjuvant Treatment in the Phase 2 I-SPY 2 TRIAL for Stage 2-3 Breast Cancer-

SGEN : 62.89 (-0.17%)
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced dosing of the first patient in EV-201,...

SGEN : 62.89 (-0.17%)
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (NASDAQ: SGEN) today announced dosing of the first patient in EV-201, a registrational phase...

ALPMF : 13.0100 (+2.12%)
SGEN : 62.89 (-0.17%)
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

--Study provides opportunity for accelerated approval and is expected to begin in the coming months

GNMSF : 226.0000 (-0.88%)
SGEN : 62.89 (-0.17%)
Cancer Space Last Week Update: Pipeline Expansion in Focus

Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

CTMX : 20.50 (-3.57%)
LLY : 85.95 (-0.69%)
ECYT : 4.30 (-0.81%)
SGEN : 62.89 (-0.17%)
CLSN : 4.08 (-1.69%)
AMGN : 181.90 (-0.61%)
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 26, 2017 after the close of financial markets. Following...

SGEN : 62.89 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Support & Resistance

2nd Resistance Point 65.01
1st Resistance Point 63.95
Last Price 62.89
1st Support Level 61.95
2nd Support Level 61.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart